LYON, France and CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil BEYEN, Chief
LYON, France and CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the presentation of two posters at
Meeting held in closed session on June 26, 2020 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting LYON, France, May 26, 2020 (GLOBE NEWSWIRE) -- Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical
LYON, France, May 07, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
Conference call and webcast on Thursday, May 7 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 Trial: More than 75% of the planned ~ 500 patients enrolled Fast-Drack designation granted by U.S. FDA Trial to continue as planned after third independent safety review Interim superiority analysis expected
LYON, France and CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a
LYON, France , April 30, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2020 first
Fast Track designation for eryaspase underscores the urgent need for potential new treatment options for patients with second line metastatic pancreatic cancer LYON, France and CAMBRIDGE, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage
More than 75% of the planned ~ 500 patients enrolled in the trial Trial to continue as planned after third safety review by independent data monitoring committee Interim superiority analysis expected around year-end; final analysis in second half of 2021 LYON, France and CAMBRIDGE, Mass.
More than 75% of the planned ~ 500 patients enrolled in the trial Trial to continue as planned after third safety review by independent data monitoring committee Interim superiority analysis expected around year-end; final analysis in second half of 2021 LYON, France , April 20, 2020 (GLOBE
